Cargando…

Treatment of severe Mycobacterium avium complex pulmonary disease with adjunctive amikacin and clofazimine versus standard regimen alone: a retrospective study

Addition of intravenous amikacin and clofazimine to recommended rifamycin-ethambutol-macrolide regimens yields favourable outcomes in severe M. avium complex pulmonary disease (MAC-PD). This five-drug regimen should be considered in select MAC-PD patients. https://bit.ly/30dxdRj

Detalles Bibliográficos
Autores principales:	Zweijpfenning, Sanne M.H., Kops, Stephan E.P., Boeree, Martin J., Kuipers, Saskia, van Ingen, Jakko, Hoefsloot, Wouter, Magis-Escurra, Cecile
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2021
Materias:	Research Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607114/ https://www.ncbi.nlm.nih.gov/pubmed/34820449 http://dx.doi.org/10.1183/23120541.00466-2021

Ejemplares similares

Subtle immunodeficiencies in nodular–bronchiectatic Mycobacterium avium complex lung disease
por: Bruno, Mariolina, et al.
Publicado: (2020)

Mycobacterium Growth Indicator Tube Time-To-Positivity Can Serve As an Early Biomarker of Treatment Response in Mycobacterium avium Complex Pulmonary Disease
por: Danho, Rabi, et al.
Publicado: (2022)

Immune defects in patients with pulmonary Mycobacterium abscessus disease without cystic fibrosis
por: Schuurbiers, Milou M.F., et al.
Publicado: (2020)

High-dose rifampicin in tuberculosis: Experiences from a Dutch tuberculosis centre
por: Seijger, Charlotte, et al.
Publicado: (2019)

Outcomes of Inhaled Amikacin and Clofazimine-Containing Regimens for Treatment of Refractory Mycobacterium avium Complex Pulmonary Disease
por: Kim, Bo-Guen, et al.
Publicado: (2020)

Mycobacterium xenopi Clinical Relevance and Determinants, the Netherlands
por: van Ingen, Jakko, et al.
Publicado: (2008)

Epidemiology of Mycobacterium bovis Disease in Humans, the Netherlands, 1993–2007
por: Majoor, Christof J., et al.
Publicado: (2011)

Safety and Outcomes of Amikacin Liposome Inhalation Suspension for Mycobacterium abscessus Pulmonary Disease: A NTM-NET study
por: Henriette Zweijpfenning, Sanne Maria, et al.
Publicado: (2022)

The role of rifampicin within the treatment of Mycobacterium avium pulmonary disease
por: Schildkraut, Jodie A., et al.
Publicado: (2023)

New and Repurposed Drugs for the Treatment of Active Tuberculosis: An Update for Clinicians
por: Aguilar Diaz, Jessica M, et al.
Publicado: (2023)

The Antipsychotic Thioridazine Shows Promising Therapeutic Activity in a Mouse Model of Multidrug-Resistant Tuberculosis
por: van Soolingen, Dick, et al.
Publicado: (2010)

805. Amikacin Liposome Inhalation Suspension (ALIS) Add-on Therapy for Refractory Mycobacterium avium Complex (MAC) Lung Disease: Effect of In Vitro Amikacin Susceptibility on Sputum Culture Conversion
por: Brown-Elliott, Barbara A, et al.
Publicado: (2018)

Role of Clofazimine in Treatment of Mycobacterium avium Complex
por: Nasiri, Mohammad Javad, et al.
Publicado: (2021)

The epidemiology of nontuberculous mycobacterial pulmonary disease in the Netherlands
por: Schildkraut, Jodie Anne, et al.
Publicado: (2021)

Novel Administration of Clofazimine for the Treatment of Mycobacterium avium Infection
por: Valinetz, Ethan, et al.
Publicado: (2020)

Amikacin Liposome Inhalation Suspension for Mycobacterium avium Complex Lung Disease: A 12-Month Open-Label Extension Clinical Trial
por: Winthrop, Kevin L., et al.
Publicado: (2021)

Amikacin liposome and Mycobacterium avium complex: A systematic review
por: Zangiabadian, Moein, et al.
Publicado: (2022)

Amikacin Liposomal Inhalation Suspension in the Treatment of Mycobacterium abscessus Lung Infection: A French Observational Experience
por: Chiron, Raphael, et al.
Publicado: (2022)

Prediction of Moxifloxacin Concentrations in Tuberculosis Patient Populations by Physiologically Based Pharmacokinetic Modeling
por: Litjens, Carlijn H. C., et al.
Publicado: (2021)

Aerosolized amikacin for treatment of pulmonary Mycobacterium avium infections: an observational case series
por: Davis, Kala K, et al.
Publicado: (2007)

Evaluating the efficacy of inhaled amikacin as an adjunct to intravenous combination therapy (ceftazidime and amikacin) in pediatric cystic fibrosis pulmonary exacerbation
por: Rakhshan, Amin, et al.
Publicado: (2023)

Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment-Refractory Nontuberculous Mycobacterial Lung Disease
por: Rubino, Christopher M., et al.
Publicado: (2021)

Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease
por: Shirley, Matt
Publicado: (2019)

Correction to: Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment‑Refractory Nontuberculous Mycobacterial Lung Disease
por: Rubino, Christopher M., et al.
Publicado: (2021)

High mortality in patients with Mycobacterium avium complex lung disease: a systematic review
por: Diel, Roland, et al.
Publicado: (2018)

Clofazimine for the treatment of tuberculosis
por: Stadler, Jacob A. M., et al.
Publicado: (2023)

Correction to: Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease
por: Shirley, Matt
Publicado: (2019)

Comparison of Treatment Outcomes of Cavitary Mycobacterium avium Complex Pulmonary Disease with Streptomycin or Amikacin Use
por: Kim, Seong Min, et al.
Publicado: (2023)

Otomastoiditis Caused by Mycobacterium abscessus, the Netherlands
por: van Ingen, Jakko, et al.
Publicado: (2010)

A Clofazimine-Containing Regimen Confers Improved Treatment Outcomes in Macrophages and in a Murine Model of Chronic Progressive Pulmonary Infection Caused by the Mycobacterium avium Complex
por: Lee, Ju Mi, et al.
Publicado: (2021)

Time-to-positivity of Mycobacterium avium complex in broth culture associates with culture conversion
por: Mingora, Christina M., et al.
Publicado: (2022)

Management of Drug Toxicity in Mycobacterium avium Complex Pulmonary Disease: An Expert Panel Survey
por: van Ingen, Jakko, et al.
Publicado: (2020)

Clofazimine-induced Hair Pigmentation
por: Philip, Mariam, et al.
Publicado: (2012)

Cysteamine/Cystamine Exert Anti-Mycobacterium abscessus Activity Alone or in Combination with Amikacin
por: Palucci, Ivana, et al.
Publicado: (2023)

The tough process of unmasking the slow-growing mycobacterium: case report of Mycobacterium microti infection
por: van de Weg, Cornelia A. M., et al.
Publicado: (2019)

Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use
por: Hoy, Sheridan M.
Publicado: (2021)

Amikacin liposome inhalation suspension clinical benefit–risk assessment for refractory Mycobacterium avium complex lung disease
por: Marras, Theodore K., et al.
Publicado: (2022)

Characterization of Mycobacterium orygis as M. tuberculosis Complex Subspecies
por: van Ingen, Jakko, et al.
Publicado: (2012)

Clofazimine for Rapidly Growing Mycobacterial Infections
por: Carey, George B, et al.
Publicado: (2017)

Clofazimine induced methemoglobinemia – Points to be focussed
por: Thangaraju, Pugazhenthan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_9h8d8df110rj507oe30tdenfa1